Genagon Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 3
Employees
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $235K
Latest Deal Amount
  • Investors
  • 2

Genagon Therapeutics General Information

Description

Developer of bio-pharmaceuticals products designed to increase response rates in immuno-oncology. The company's products are used to identify novel pathways in immune cells and discovered a new mechanism that cancers use to inhibit the innate immune system, enabling doctors to offer treatment for oncology and inflammatory diseases.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Therapeutic Devices
Primary Office
  • Nanna Svartz Väg 2
  • Karolinska University Hospital
  • 171 65 Solna
  • Sweden
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Genagon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 26-Jan-2016 $235K 00000 Completed Generating Revenue
To view Genagon Therapeutics’s complete valuation and funding history, request access »

Genagon Therapeutics Executive Team (9)

Name Title Board Seat Contact Info
Moa Fransson Ph.D Chief Executive Officer
Simon Fredriksson Ph.D Co-Founder & Executive Vice President
Andries Blokzijl Co-Founder & Scientific Advisor
Päivi Rosti Co-Founder
Roger Henriksson Ph.D Advisor
You’re viewing 5 of 9 executive team members. Get the full list »

Genagon Therapeutics Board Members (5)

Name Representing Role Since
Anders Nordström Self Chairman 000 0000
Johan Lund Ph.D Self Board Member 000 0000
Karin von Wachenfeldt Ph.D Self Board Member 000 0000
Richard Åhlberg Ph.D Genagon Therapeutics Board Member 000 0000
Svein Arild Mathisen Genagon Therapeutics Board Member 000 0000
To view Genagon Therapeutics’s complete board members history, request access »

Genagon Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genagon Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Almi Invest Venture Capital Minority 000 0000 000000 0
Beijer Ventures Venture Capital Minority 000 0000 000000 0
To view Genagon Therapeutics’s complete investors history, request access »